Bank Julius Baer & Co. Ltd Zurich Lowers Stock Holdings in AbbVie Inc. $ABBV

Bank Julius Baer & Co. Ltd Zurich cut its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 3.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 46,690 shares of the company’s stock after selling 1,538 shares during the period. Bank Julius Baer & Co. Ltd Zurich’s holdings in AbbVie were worth $8,667,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Marshall & Sullivan Inc. WA acquired a new position in shares of AbbVie in the second quarter worth $25,000. TD Capital Management LLC raised its position in AbbVie by 82.9% in the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after purchasing an additional 58 shares in the last quarter. Spurstone Advisory Services LLC purchased a new position in shares of AbbVie in the 2nd quarter valued at about $28,000. Financial Gravity Companies Inc. acquired a new position in shares of AbbVie during the second quarter worth about $36,000. Finally, Bear Mountain Capital Inc. increased its stake in shares of AbbVie by 480.6% during the second quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after buying an additional 173 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Up 2.9%

ABBV opened at $236.12 on Friday. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The stock has a market capitalization of $417.31 billion, a P/E ratio of 112.44, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. The business’s 50-day simple moving average is $226.81 and its 200-day simple moving average is $205.22.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The firm’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter last year, the business posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a yield of 2.9%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is currently 524.24%.

Wall Street Analysts Forecast Growth

Several research analysts have commented on ABBV shares. Scotiabank started coverage on shares of AbbVie in a report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price target for the company. Morgan Stanley boosted their target price on shares of AbbVie from $250.00 to $255.00 and gave the stock an “overweight” rating in a research note on Friday, August 1st. Daiwa America upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 7th. DZ Bank cut AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective for the company. in a research report on Tuesday, November 4th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $289.00 price objective (up previously from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $241.85.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.